Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 10/20 | 0.85 |
| ▸ | HTR3E | A5X5Y0 | 4/20 | 0.85 |
| ▸ | HTR3B | O95264 | 4/20 | 0.85 |
| ▸ | HTR3A | P46098 | 4/20 | 0.85 |
| ▸ | HTR3D | Q70Z44 | 4/20 | 0.85 |
| ▸ | HTR3C | Q8WXA8 | 4/20 | 0.85 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.85 |
| ▸ | TSHR | P16473 | 1/20 | 0.85 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.52 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6311102 | 0.94 | CHRNA7 (0.74) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| Pnu-282987 SCHEMBL10436185 | 0.92 | CHRNA7 (1.00) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| Pnu-282987 SCHEMBL677422 | 0.92 | CHRNA7 (1.00) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| Pnu-282987 SCHEMBL6208420 | 0.92 | CHRNA7 (1.00) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| Pnu-282987 SCHEMBL9601902 | 0.91 | CHRNA7 (0.97) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| Pnu-282987 SCHEMBL1118980 | 0.91 | CHRNA7 (0.97) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| Pnu-282987 SCHEMBL7281159 | 0.91 | CHRNA7 (0.97) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL373736 | 0.89 | CHRNA7 (1.00) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL6881216 | 0.89 | CHRNA7 (0.81) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL834016 | 0.89 | CHRNA7 (1.00) | CHRNA7HTR3EHTR3BHTR3AHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060160835-A1 | Methods and compositions for treatment of central nervous system disorders | BENCHERIF MEROUANE | 2006-07-20 | — | — | US | claimed |
| US-7067261-B2 | Methods and compositions for treatment of central nervous system disorders | TARGACEPT, INC. (US) | 2006-06-27 | — | — | US | claimed |
| EP-1381603-A2 | QUINUCLIDINE-SUBSTITUEDARYL MOIETIES FOR TREATMENT OF DISEASE ( NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS ) | PHARMACIA & UPJOHN COMPANY (US) | 2004-01-21 | — | — | EP | claimed |
| US-6492386-B2 | TREATING A DISEASE OR CONDITION IN A MAMMAL, WHEREIN THE ALPHA 7 NICOTINIC-ACETYLCHOLINE RECEPTOR IS IMPLICATED | PHARMACIA & UPJOHN COMPANY | 2002-12-10 | — | — | US | claimed |
| US-6486172-B2 | ADMINISTERING TO A MAMMAL A THERAPEUTICALLY EFFECTIVE AMOUNT OF BENZAMIDE OR BENZOCARBONYLSULFIDE SUBSTITUTED 1-AZABICYCLO(2,2,2)OCT-3-YL COMPOUNDS TO TREAT THE CONDITIONS ASSOCIATED WITH DEFECTS OF NICOTINIC SUBTYPES BRAIN RECEPTORS | PHARMACIA & UPJOHN COMPANY | 2002-11-26 | — | — | US | claimed |
| US-6479510-B2 | N-((2S,3R)-2-METHYL-1-AZABICYCLO(2.2.2)OCT-3-YL)-4-(4-HYDROXYP HENOXY)- BENZAMIDE FOR EXAMPLE; TREATING DISEASES OF THE ALPHA-7-NICOTINIC ACETYLCHOLINE RECEPTOR I.E. SCHIZOPHRENIA, OR PSYCHOSIS | PHARMACIA & UPJOHN COMPANY | 2002-11-12 | — | — | US | claimed |
| US-20020052389-A1 | Treating a disease or condition in a mammal, wherein the alpha 7 nicotinic-acetylcholine receptor is implicated | PHARMACIA & UPJOHN COMPANY | 2002-05-02 | — | — | US | claimed |
| US-20020049225-A1 | Quinuclidine-substituted aryl compounds for treatment of disease | PHARMACIA & UPJOHN COMPANY | 2002-04-25 | — | — | US | claimed |
| US-20020040035-A1 | Quinuclidine-substituted aryl compounds for treatment of disease | PHARMACIA & UPJOHN COMPANY | 2002-04-04 | — | — | US | claimed |
| WO-2002016356-A2 | QUINUCLIDINE-SUBSTITUTED ARYL MOIETIES FOR TREATMENT OF DISEASE (NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS) | PHARMACIA & UPJOHN COMPANY (US) | 2002-02-28 | — | — | WO | claimed |
| WO-2002016357-A2 | QUINUCLIDINE-SUBSTITUTED ARYL MOIETIES FOR TREATMENT OF DISEASE (NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS) | PHARMACIA & UPJOHN COMPANY (US) | 2002-02-28 | — | — | WO | claimed |
| WO-2002016358-A2 | QUINUCLIDINE-SUBSTITUTED ARYL MOIETIES FOR TREATMENT OF DISEASE (NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS) | PHARMACIA & UPJOHN COMPANY (US) | 2002-02-28 | — | — | WO | claimed |
| US-20140234270-A1 | TREATMENT WTH ALPHAT SELECTIVE LIGANDS | TARGACEPT, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| EP-2484363-A1 | (2S,3R)-N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-5-methylthiophene-2-carboxamide | Targacept, Inc. (US) | 2012-08-08 | — | — | EP | disclosed |
| EP-2409703-A1 | Treatment with alpha7-selective ligands | Targacept, Inc. (US) | 2012-01-25 | — | — | EP | disclosed |
| US-20110262407-A1 | TREATMENT WITH ALPHA7 SELECTIVE LIGANDS | TARGACEPT, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-20020040035-A1 | Quinuclidine-substituted aryl compounds for treatment of disease | PHARMACIA & UPJOHN COMPANY | 2002-04-04 | — | — | US | disclosed |
| WO-2002016356-A2 | QUINUCLIDINE-SUBSTITUTED ARYL MOIETIES FOR TREATMENT OF DISEASE (NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS) | PHARMACIA & UPJOHN COMPANY (US) | 2002-02-28 | — | — | WO | disclosed |
| WO-2002016358-A2 | QUINUCLIDINE-SUBSTITUTED ARYL MOIETIES FOR TREATMENT OF DISEASE (NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS) | PHARMACIA & UPJOHN COMPANY (US) | 2002-02-28 | — | — | WO | disclosed |
| WO-2002016357-A2 | QUINUCLIDINE-SUBSTITUTED ARYL MOIETIES FOR TREATMENT OF DISEASE (NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS) | PHARMACIA & UPJOHN COMPANY (US) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160835-A1 | Methods and compositions for treatment of central nervous system disorders | JAK2, ERBB2, ERBB3 | CHRNA7 46/4885HTR3E 349/4885HTR3B 139/4885 |
| US-20140234270-A1 | TREATMENT WTH ALPHAT SELECTIVE LIGANDS | CHRNA7, CHRNA2, CHRNA4 | CHRNA7 1/4885HTR3E 312/4885HTR3B 108/4885 |
| US-20020049225-A1 | Quinuclidine-substituted aryl compounds for treatment of disease | UGT1A1, NAT1, SLC10A1 | CHRNA7 365/4885HTR3E 1415/4885HTR3B 628/4885 |
| US-20020040035-A1 | Quinuclidine-substituted aryl compounds for treatment of disease | UGT1A1, NAT1, SLC10A1 | CHRNA7 365/4885HTR3E 1415/4885HTR3B 628/4885 |
| US-20020052389-A1 | Treating a disease or condition in a mammal, wherein the alpha 7 nicotinic-acetylcholine receptor is implicated | CHRNA7, CHRNA1, CHRNB1 | CHRNA7 1/4885HTR3E 2024/4885HTR3B 942/4885 |
| US-20110262407-A1 | TREATMENT WITH ALPHA7 SELECTIVE LIGANDS | CHRNA7, CHRNA4, CHRNA2 | CHRNA7 1/4885HTR3E 378/4885HTR3B 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.